The short answer
Cross-border medical advertising requires separate review by advertiser, service or product category, destination market, and distribution channel. Record evidence and approval ownership for every claim, then publish only after the client's designated specialist completes the final review.
Japan and Korea have different regulatory paths for medical services, medicines and devices, cosmetics, and foreign-patient acquisition. Do not treat these categories as one rule set. Identify the advertiser, service or product category, distribution market, and responsible entity before drafting claims.
The Korea Health Industry Development Institute publishes an online medical advertising guide for medical institutions and registered businesses attracting foreign patients. Japan's Ministry of Health, Labour and Welfare publishes the Medical Advertising Guidelines and explains that, where those rules apply, using a foreign language does not remove an advertisement from scope.
A claims matrix should record the claim, evidence file, destination market, responsible reviewer, approval date, and where the approved wording appears in the advertisement and landing page. Unsupported claims are removed before production rather than left for platform review.
Applicability depends on the advertiser, audience, media, and commercial structure. The client or its designated specialist makes the final legal, medical, licensing, labeling, and advertising decision for each market.
RIVACTA does not provide legal or medical advice or approval. The Fit Call is a pre-contract fit check with no research, strategy, or deliverable. Market-specific advertising and operating diagnosis begins only after a paid Market Diagnostic agreement.
Evidence and sources
- Korea Health Industry Development Institute: Online Medical Advertising Guide for Foreign Patient Acquisition
- Ministry of Health, Labour and Welfare of Japan: Advertising regulations for hospitals and clinics under Japan's Medical Care Act
- Ministry of Health, Labour and Welfare of Japan: Medical Advertising Guidelines Q&A